Standard BioTools sells lab instruments and consumables that help scientists measure proteins and genes, like a high-tech microscope for biology research.
Revenue was USD 0.09B in 2025, with gross margin near 49%, but net margin was -103%—the company loses money on every sale, so no segment currently pays the bills.
Its patented CyTOF and SomaScan platforms are hard to copy, but competition from Illumina and Thermo Fisher is eroding pricing power.

Key events, in time order
None yet
None yet
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice